Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy

Clinical trial NCT07537777 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07537777
Sponsor: Nanfang Hospital, Southern Medical University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma (HCC)First-line Targeted Therapy Failure Oligometastatic Hepatocellular Carcinoma Benmelstobart Anlotinib SBRT

Start date: 2026-04-20
Primary completion: 2028-01-31
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.